Monitoring Patients With Inflammatory Bowel Disease at High Risk of Anal Cancer.

Autor: Cairns CA; Department of Surgery, Division of General and Oncologic Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA., Cross RK; Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, Maryland, USA., Khambaty M; Department of Medicine, Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA., Bafford AC; Department of Surgery, Division of Colon and Rectal Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jazyk: angličtina
Zdroj: The American journal of gastroenterology [Am J Gastroenterol] 2024 Jan 01; Vol. 119 (1), pp. 81-86. Date of Electronic Publication: 2023 Sep 18.
DOI: 10.14309/ajg.0000000000002503
Abstrakt: Anal cancer is a rare but deadly disease that disproportionately affects patients with inflammatory bowel disease (IBD). Rates of adenocarcinoma and human papillomavirus-related squamous cell carcinoma have been consistently demonstrated to be higher in patients with ulcerative colitis and Crohn's disease. Despite this increased risk, uniform screening, diagnosis, and treatment algorithms are lacking. This review describes the most recent literature surrounding anal cancer in the IBD population as well as the unique challenges inherent in diagnosing and treating this population. We conclude by proposing a new screening motif based off literature review and multidisciplinary clinical experience that aims to increase early detection of anal cancers in the IBD population.
(Copyright © 2023 by The American College of Gastroenterology.)
Databáze: MEDLINE